Compare iShares MSCI Indonesia ETF (EIDO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Twist Bioscience Corp — how do they compare? iShares MSCI Indonesia ETF trades at $12.65, while Twist Bioscience Corp trades at $122.32 (market cap $7.72B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| EIDO | TWST | |
|---|---|---|
52-Week High | $19.22 | $124.88 |
52-Week Low | $10.80 | $24.16 |
Market Cap | — | $7.72B |
Sector | — | Health |
Enterprise Value | — | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $12.64, down 0.86% on the day, with a bearish technical signal from moving averages and mixed oscillators. The stock faces headwinds from foreign capital outflows in Asian equities and Indonesia's economic exposure. A dividend of $0.23 is scheduled for payment in June 2026, offering income potential amid weak price action.
The outlook remains cautious due to technical downtrends and macroeconomic pressures on Indonesian assets. Investment appeal hinges on valuation discounts and potential policy support, but risks include currency volatility and limited earnings growth. Investors require patience for a turnaround.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
